導入化学療法としてのTPF療法の安全性

概要

論文の詳細を見る
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy, while a durable, effective treatment for those with locally advanced squamous cell cancer of the head and neck, also induces toxicity problems, such as neutropenia. We retrospectively compared TPF-based and cisplatin, 5-fluorouracil (PF)-based induction chemotherapy to clarify toxicity and safety. Subjects numbered 54-19 undergoing TPF-based and 35 PF-based induction chemotherapy. Although the 2 groups did not differ significantly in other toxicities e.g., anorexia, diarrhea, and renal dysfunction, 89% of TPF group had grade 3-4 neutropenia significantly more often. Neutropenia was limited to a few days, making its occurrence easy to predict and its toxicity easier to manage in TPF-based induction chemotherapy.
2011-05-01